In addition to the specific classification name of the tumor, the size of the tumor, the clean resection of each margin, the site and number of lymph node metastases, and the presence of infiltration in the vascular lymphatic vessels and other tissues, there are some important immunological indicators that can indicate the prognosis in the postoperative pathology of breast cancer, and the analysis of these indicators can guide the treatment and estimate the prognosis. The following are the common immune indicators that may be present in the examination of each hospital and their interpretation for reference only. ER: estrogen receptor, positive indicates a better prognosis than negative patients, the more plus signs the better. PR: progesterone receptor, positive indicates a better prognosis than negative patients. ER and PR are present in normal breast epithelial cells; when cells become cancerous, ER and PR appear partially and completely absent. If ER and/or PR are still retained, the growth and proliferation of the breast cancer cell is still regulated by endocrine control and is called hormone-dependent breast cancer; if ER and/or PR are absent, the growth and proliferation of the breast cancer cell is no longer regulated by endocrine control and is called non-hormone-dependent breast cancer. If both are positive, the prognosis is best. If one is positive and one is negative, estrogen positivity is better than progesterone positivity. The prognosis is not good for both negatives. Positive cases can be treated with postoperative or preoperative endocrine therapy. Her-2 (CerbB-2): human epidermal growth factor receptor 2, a proto-oncogene. Its overexpression, i.e. the presence of a plus sign, indicates that the patient has a poor prognosis. It also suggests that patients are prone to axillary lymph node metastasis and possible deficiency of both of these hormone receptors. Its expression is positively correlated with breast cancer grade, lymph node metastasis and clinical stage, and the higher the expression rate, the worse the prognosis may be. However, those with more than two plus signs in Fish test have the possibility of biologically targeted therapy. That is, with trastuzumab (Herceptin). All three of these patients are negative, and are now medically known as “triple negative” breast cancer, with a relatively poor prognosis and lack of drug treatment. E-Cadherin: E-calcified adhesion protein is one of the transmembrane protein isoforms in the calcium adhesion protein family of molecules, which is expressed exclusively at the adherens junctions and plays an important role in maintaining the integrity, polarity, morphology and organization of epithelial cells. Its high expression indicates a good prognosis. Ki-67index: It is a proliferative antigen that responds to cell proliferation, and its expression is associated with breast cancer development and progression, and is a poor prognostic factor. The higher the value, the worse the prognosis. P53: It is a tumor suppressor gene and its mutation indicates poor prognosis; breast cancer cells with high P53 mutation rate have high proliferation activity, poor differentiation, high malignancy, aggressiveness and high lymph node metastasis rate. CK5/6: It is a cytokeratin, and the higher the histological grade and tumor stage, the higher its expression rate, and the overall positive prognosis is poor. EGFR: Epidermal growth factor receptor, the higher the histological grade and tumor stage, the higher the expression rate, and the overall positive indicates poor clinical prognosis. VEGF: Vascular endothelial growth factor, high expression indicates poor prognosis. TOP-II: DNA topoisomerase II, high expression indicates higher tumor proliferation and malignancy. PCNA: proliferating cell nuclear antigen, positive prognosis is poor. P170: a multidrug resistance gene whose overexpression is detrimental to treatment. nm23: a gene associated with malignant metastasis, and reduced gene expression level is a high risk factor for lymphatic metastasis of breast cancer. Her-1: similar to Her-2 in the previous section, poorly positive. DNA ploidy: Aneuploidy predicts tumorigenesis. CD44V6: It is a protein, high expression suggests poor prognosis. Ck14, Ck17 and CK7: have similar reference standards as the preceding Ck5/6. Bcl-2: It is an apoptosis-suppressing gene, and its positive expression suggests a high degree of tumor grading and few lymph node metastases. PS2: PS2 may be more useful than ER assay in predicting response to endocrine therapy, and PS2 expression is the best indicator of response to endocrine therapy in breast cancer.